<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00518583</url>
  </required_header>
  <id_info>
    <org_study_id>06BR01</org_study_id>
    <nct_id>NCT00518583</nct_id>
  </id_info>
  <brief_title>Phase II Study in Patients With Operable Breast Cancer</brief_title>
  <official_title>A Phase II Study of Pre-Operative Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, and Trastuzumab in Patients With Operable Breast Cancer Over-expressing Her2-neu</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aptium Oncology Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Biotech Products, L.P.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aptium Oncology Research Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety and efficacy of the combination PLD, paclitaxel, and
      trastuzumab in patients with operable breast cancer. Patients will be treated with the
      combination for 18 weeks, followed by surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identify the pCR rate of neoadjuvant chemotherapy using the proposed 18-week regimen of PLD + paclitaxel + trastuzumab</measure>
    <time_frame>within 18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify the complete response rate</measure>
    <time_frame>within 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify the partial response rate</measure>
    <time_frame>within 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify the overall response rate</measure>
    <time_frame>within 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate changes in cardiac function</measure>
    <time_frame>within study participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitor safety and tolerability of neoadjuvant chemotherapy using the proposed 18 week regimen</measure>
    <time_frame>within study participation</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin (Doxil)</intervention_name>
    <description>Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly</description>
    <other_name>taxol (paclitaxel)</other_name>
    <other_name>herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dx of clinical T1c-T3, N0-1, M0 breast cancer

          -  Interval between diagnosis and consent of &lt;- 62 days

          -  Life expectancy of 10 years

          -  LVEF by MUGA &gt;= lower limit of normal for the testing facility

          -  Negative serum pregnancy test

          -  Adequate bone marrow, renal, liver function

          -  Negative bone scan

          -  HRT discontinued before study entry

          -  Adequate contraceptive methods

        Exclusion Criteria:

          -  Male breast cancer

          -  Less than 21 years of age

          -  Ulceration, infiltration of the skin, complete fixation or severe skin edema

          -  N3 disease in which nodes are matted and fixed

          -  Suspicious palpable supraclavicular nodes

          -  CT evidence of malignant internal mammary nodes

          -  Pregnancy or breast feeding at time of study entry

          -  Prior therapy for breast cancer

          -  Prior anthracycline for any malignancy

          -  Prior breast malignancy of the contralateral breast

          -  Prior non-breast malignancy within 5 years

          -  Non-malignant disease that would preclude follow up

          -  MI within 6 months, NYHA Class II or greater heart failure

          -  Psychiatric disorders or conditions that would preclude provision of informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Macdonald, MD</last_name>
    <role>Study Director</role>
    <affiliation>CMO Aptium Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence St. Joseph Medical Hospital</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Outpatient Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Regional Medical Center Comprehensive Cancer Center</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Regional Cancer Center West</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John H. Stroger, Jr. Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maimonides Cancer Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent Comprehensive Cancer Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2007</study_first_submitted>
  <study_first_submitted_qc>August 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2007</study_first_posted>
  <last_update_submitted>January 14, 2010</last_update_submitted>
  <last_update_submitted_qc>January 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Marti McKinley</name_title>
    <organization>Aptium Oncology Research Network</organization>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Over-expressing Her2-neu</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

